Key Insights• According to the research report, "India Point of Care Diagnostics Market Outlook, 2031," published by Bonafide Research, the India Point of Care Diagnostics Market is anticipated to add to more than 2.32 Billion by 2026-31.• The primary structural catalyst driving India’s Point-of-Care (POC) diagnostics market is the government-backed expansion of rural health networks. Through public initiatives like the operationalization of over 181,000 Ayushman Arogya Mandirs (Health and Wellness Centres), primary care networks are systematically deploying portable diagnostic devices to underserved communities. A major technological breakthrough transforming this ecosystem is the deployment of microfluidic chip platforms and battery-operated, portable RT-PCR systems (such as Truenat). Originally scaled for widespread tuberculosis screening, these microchip-based molecular platforms allow community health workers to perform rapid, lab-grade DNA and RNA extraction for infectious diseases in ambient temperatures without requiring cold-chain infrastructure or central laboratory facilities.• Point-of-care testing in India is transitioning from offline, manual test strips to cloud-connected biosensors integrated directly into the national digital health ecosystem. Under the Ayushman Bharat Digital Mission (ABDM), modern POCT hardware deployed across primary health centers and mobile diagnostic clinics features wireless Bluetooth and cellular connectivity. This connectivity allows real-time health metrics such as blood glucose, HbA1c, lipid profiles, and viral panel results to sync directly into patient ABHA (Ayushman Bharat Health Account) records.• India's point-of-care diagnostic market is shifting away from heavy import reliance toward indigenous, low-cost manufacturing.

Backed by the government's Production Linked Incentive (PLI) scheme for medical devices and supportive CDSCO (Central Drugs Standard Control Organisation) regulatory frameworks, domestic manufacturers are scaling local production of microfluidic chips, diagnostic reagents, and biosensor cartridges. A key innovation in this space is the development of ultra-low-cost paper-based biosensors and handheld multiplex immunoassays, which significantly lower the cost per test for endemic conditions like dengue, malaria, chikungunya, and typhoid.Market Outlook• The market outlook for point-of-care diagnostics in India is anchored by an increasing focus on managing the country's dual disease burden combining widespread endemic infectious diseases with a surge in chronic metabolic conditions. As diabetes, hypertension, and cardiovascular diseases rise across urban and semi-urban populations, demand for low-cost, continuous multi-parametric monitoring devices (such as HbA1c, lipid panel, and cardiac biomarker kits) is expanding rapidly. Public healthcare budgets are prioritizing decentralized screening to catch chronic conditions early, shifting the point of care from tertiary hospitals toward community centers, local pharmacy clinics, and home health settings.• Key domestic and international commercial developers operating across the Indian point-of-care market include Molbio Diagnostics, Trivitron Healthcare, Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation (Cepheid), and Agappe Diagnostics, operating under medical device licensing frameworks managed by the Central Drugs Standard Control Organisation (CDSCO) and guided by public health research bodies such as the Indian Council of Medical Research (ICMR).Market DynamicsDriver: Surging burden of chronic and lifestyle diseasesIndia is experiencing a massive rise in lifestyle-related and chronic illnesses particularly diabetes, hypertension, and cardiovascular ailments alongside a persistent burden of infectious diseases. This health landscape creates an urgent, widespread demand for decentralized, rapid, and cost-effective point-of-care (POC) testing solutions that allow immediate screening and ongoing monitoring outside major centralized urban laboratories. Challenge: Infrastructure gaps and disparities in rural awarenessWhile urban centers have embraced rapid testing, rural and remote regions where a significant portion of the population resides face infrastructure limitations, a lack of trained medical personnel at smaller clinics, and lower health literacy. Bridging this knowledge gap and establishing reliable cold-chain or power supplies in underserved areas remain key operational barriers.Trend: Miniaturization, smartphone connectivity, and localized manufacturingThe market is shifting rapidly toward ultra-portable, pocket-sized diagnostic tools integrated with smartphone applications and cloud connectivity (IoT).

Concurrently, national self-reliance initiatives and local private investments are pushing domestic manufacturing of affordable microfluidic and molecular POC kits.Segment Analysis India Point of Care Diagnostics By Product• Glucose monitoring kits in India are evolving from basic glucometer-and-strip combinations toward more connected and lower-burden monitoring workflows. Conventional capillary testing remains important, but product development increasingly emphasizes compact meters, alternative sampling approaches, digital result storage, smartphone connectivity, and integration with diabetes-management applications. A distinctive regulatory feature is that India has explicitly addressed glucometer test-strip standards, while CDSCO classifies IVDs according to risk and oversees manufacturing, importing, performance evaluation, and post-market activities.• Infectious-disease POC kits in India are increasingly moving from basic rapid screening toward more specific molecular, antigen, and multiplex formats. The distinctive opportunity is the ability to bring pathogen identification closer to locations where centralized laboratory access can be slower or less practical, while still linking positive or uncertain results to confirmatory pathways. India's regulatory framework has recently become more structured around high-risk infectious-disease IVDs, with CDSCO and ICMR developing standard performance-evaluation protocols and minimum standards.• Pregnancy and fertility testing is naturally suited to decentralized use because testing can occur privately at home without an initial laboratory visit. The segment extends from conventional urine pregnancy strips to ovulation and fertility-window tests intended for repeated use, with digital readers increasingly capable of simplifying result interpretation.

In India, the broader IVD regulatory framework places these products within a risk-based medical-device environment, while self-testing creates additional requirements around instructions, sample handling, interpretation, and foreseeable user error.• Hematology POC kits are bringing selected blood measurements closer to clinical decision-making through compact analyzers, cartridges, and simplified specimen workflows. Applications can include hemoglobin, hematocrit, coagulation-related parameters, and other blood measurements where rapid information can complement conventional laboratory testing. India's decentralized-care environment creates opportunities for these systems in emergency, outpatient, community, and smaller healthcare facilities, but products must operate within the country's risk-based IVD framework.• Cardiometabolic monitoring kits in India increasingly combine immediate measurement with longer-term disease management, covering glucose, cholesterol, coagulation, and related biomarkers. A distinctive trend is the convergence of POC testing with digital health: meters and analyzers can increasingly store results, communicate with mobile applications, and support longitudinal monitoring rather than producing isolated readings.• Urinalysis kits are particularly suitable for POC because urine collection is non-invasive and reagent strips can screen several parameters without complex laboratory equipment. The segment ranges from visually interpreted dipsticks to reader-assisted platforms that standardize interpretation and electronically record results. Their distinctive role in India is the ability to provide rapid preliminary information in settings where full laboratory infrastructure may not be immediately available, while abnormal findings can trigger more comprehensive testing.• Cholesterol test strips bridge conventional laboratory lipid testing and decentralized cardiometabolic screening.

Their value lies in obtaining lipid-related information from a small capillary sample during a consultation, community screening interaction, pharmacy-based service, or home-monitoring episode. Product differentiation is increasingly shifting toward compact readers, reduced sample requirements, automated interpretation, digital record keeping, and integration with broader cardiovascular-risk assessment.• Other Products covers specialized POC applications such as cardiac biomarkers, inflammatory markers, electrolytes, blood gases, coagulation, toxicology, reproductive biomarkers, and multi-analyte systems. This segment is particularly relevant to India's push toward locally developed diagnostic technologies because a single compact platform can potentially support several clinical applications through interchangeable cartridges or assay modules. India Point of Care Diagnostics By Technology/Platform• Lateral flow assays remain highly compatible with India's decentralized diagnostic environment because they require relatively little equipment and can provide results close to the patient. They are applicable across infectious diseases, pregnancy, fertility, and other rapid-screening categories, with formats designed for professional and consumer use. Their next stage of development is increasingly focused on reader-assisted interpretation, multiplexing, and improved analytical specificity rather than relying solely on visual lines.• PCR and isothermal nucleic-acid amplification are enabling more sophisticated pathogen detection to move closer to the point of care through compact analyzers and integrated cartridges. These platforms can combine sample preparation, amplification, and detection, reducing dependence on full-scale laboratory infrastructure.

India is developing a particularly relevant regulatory ecosystem for this technology: CDSCO and ICMR have established standard performance-evaluation protocols and minimum standards for high-risk infectious-disease IVDs, alongside guidance for validating rapid pathogen identification and antimicrobial-susceptibility diagnostics.• Microfluidics and immunoassays allow multiple laboratory functions to be compressed into small cartridges and portable instruments. Microfluidic systems can control tiny sample volumes and integrate preparation, reaction, separation, and detection, while immunoassays can measure hormones, proteins, antigens, antibodies, and other biomarkers. In India, these technologies are particularly relevant to platforms designed to reproduce selected laboratory capabilities outside conventional diagnostic laboratories.• Dipsticks and test strips remain among the most accessible POC technologies in India because they require minimal equipment and can be used directly at the testing site. Urinalysis, glucose monitoring, pregnancy testing, and selected cardiometabolic applications can all use disposable strip formats. Reader-assisted versions add automated interpretation and digital result capture, creating a progression from simple visual screening to more standardized professional workflows. India Point of Care Diagnostics By End-User • Indian hospitals and critical-care centers use POC diagnostics where rapid results can complement centralized laboratory testing during acute clinical situations. Emergency departments, intensive-care units, operating environments, and other high-dependency settings can benefit from tests that reduce specimen transport and turnaround delays.

The distinctive feature is the increasing formalization of POC quality requirements: India's Medical Devices Rules classify IVDs by risk, while CDSCO oversees licensing, clinical-performance evaluation, quality compliance, and post-market activities.• Clinical and diagnostic laboratories increasingly function as the quality-management backbone for decentralized testing in India. They can support method verification, quality control, calibration, operator training, instrument management, troubleshooting, and confirmation of POC findings when necessary. This role becomes more significant as POC systems adopt molecular diagnostics, immunoassays, microfluidics, and multi-analyte capabilities traditionally associated with centralized laboratories. CDSCO's registration framework for IVD testing laboratories and its network of laboratories for performance evaluation of analyzers, instruments, software, and reagents further connect decentralized diagnostics with formal laboratory-quality processes.• Home care and self-testing are expanding India's POC ecosystem through glucose monitoring, pregnancy and fertility testing, selected infectious-disease tests, cholesterol monitoring, and other consumer-oriented applications. The defining shift is that specimen collection, testing, and initial interpretation can occur outside professional facilities, making intuitive instructions, storage stability, error-resistant design, and clear communication of limitations especially important. India's regulatory framework places IVDs within a risk-based medical-device system and provides specific mechanisms for licensing, performance evaluation, and post-market oversight.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Point of Care Diagnostics Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Glucose Monitoring Kits• Infectious Diseases Testing Kits• Pregnancy And Fertility Testing Kits• Hematology Testing Kits• Cardiometabolic Monitoring Kits• Urinalysis Testing Kits• Cholesterol Test Strips• Other ProductsBy Technology/Platform• Lateral Flow Assays• Molecular Diagnostics (PCR/INAAT)• Microfluidics & Immunoassays• Dipsticks & Test StripsBy End-User• Hospitals & Critical Care Centers• Clinical & Diagnostic Laboratories• Home Care & Self-TestingBy Mode Of Purchase• Prescription Based Products• OTC ProductsBy Sample• Blood• Urine• Nasal and Oropharyngeal Swabs.